<DOC>
	<DOCNO>NCT01715532</DOCNO>
	<brief_summary>Primary Outcome Measures : - To compare progression free survival ( PFS ) patient unresectable hepatocellular carcinoma ( HCC ) treat transcatheter arterial chemoembolization ( TACE ) without Huachansu , correlation PFS expression peripheral Na+/K+-ATPase α3 family . Secondary Outcome Measures : - To compare overall survival ( OS ) , objective response rate ( ORR ) , side effect treat HCC TACE plus Huachansu TACE alone . Exploratory Outcome Measures : - To evaluate correlation prognosis expression peripheral Na+/K+-ATPase α3 family .</brief_summary>
	<brief_title>Role Huachansu Treating Hepatocellular Carcinoma Correlation With Na+/K+-ATPase</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Male female subject 1875 year age . Diagnosis hepatocellular carcinoma . Biopsy prefer method diagnosis ( option 1 ) . As far clinically possible , result biopsy obtained confirm diagnosis prior initiation investigational product administration.. Nonbiopsy criterion allow case biopsy result unavailable biopsy procedure clinically indicate ( option 2 ) . ( Option 1 : Biopsyproven HCC ( histology cytology ) ; Option 2 patient must fulfill follow criterion : i. Radiological evidence HCC show lesion arterial hypervascularity venous phase washout either dynamic ( triplephase ) , contrastenhanced compute tomography abdomen OR dynamic ( triplephase ) contrast ( gadolinium ) enhance MRI , AND ii . Serology positive hepatitis B C , AND iii . Alpha fetoprotein &gt; 400 μg/L time diagnosis . ) No metastasis outside liver . Unable unwilling receive radical surgery . No prior transcatheter arterial chemoembolization . No prior treatment bufalins include Huachansu . At least one measurable untreated lesion . All subject must least one measurable lesion unidimensionally CT MRI scan , accord modify RECIST HCC , previously treat surgery , irradiation , radiofrequency ablation , percutaneous ethanol acetic acid injection , cryoablation . Cirrhotic status ChildPugh Class A B . Adequate hematologic function absolute neutrophil count ≥ 1.5×109 /L , platelet count ≥ 50 x 109/L , hemoglobin ≥ 85 g/L . Signed Written Informed Consent . Subjects life expectancy least 3 month . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study risk pregnancy minimize . Previously treat target lesion irradiation , TACE , radiofrequency ablation , percutaneous ethanol acetic acid injection , cryoablation . Cirrhotic status ChildPugh Class C. Severe diseases heart , liver , kidney , etc may cause inadequate organ function History malignant tumor 5 year . Pregnant lactating woman . Mentally disordered . Participation clinical trial within month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Huachansu</keyword>
	<keyword>Na+/K+-ATPase α3</keyword>
	<keyword>transcatheter arterial chemoembolization</keyword>
	<keyword>randomize control trial</keyword>
</DOC>